News | October 02, 2014

ESC Abstracts Show Utility of Singulex's Troponin, Renal Function Tests

October 2, 2014 — Singulex Inc. announced the presentation of 10 abstracts at the European Society of Cardiology's (ESC) annual conference, which highlight the clinical utility of single molecule counting technology in the detection and quantification of biomarkers for cardiac disease, its comorbidities, and its risk factors. The conference, held in Barcelona, Spain from Aug. 30 through Sept. 3rd, also featured the first European preview of the Sgx Clarity System, a fully-automated, SMC-powered in vitrodiagnostics system targeted for launch to European hospitals and reference labs in 2016.

Three of the 10 abstracts accepted by ESC Congress 2014 were selected for oral presentations:

Ultra-sensitive troponin I strongly predicts incident coronary heart disease in the general population independently of traditional risk factors. Results from the MONICA/KORA Augsburg Case-Cohort Study
Wolfgang Koenig, M.D., Ph.D., professor of medicine/cardiology at the department of internal medicine II — cardiology at the University of Ulm Medical School, Ulm, Germany, reported that even modestly increased cardiac Troponin I (cTnI) levels are strongly associated with incident coronary heart disease (CHD) independent of standard risk factors. Using Singulex's highly sensitive cTnI research-use-only immunoassay, the long-term, population-based, prospective study found that cTnI was detectable in almost every healthy middle-aged subject. Incident CHD subjects had a higher baseline cTnI level than subjects who did not develop CHD (geometric mean 2.56 vs. 1.49 ng/L, p<0.0001).

"Singulex's highly-sensitive cTnI assay has enabled us to predict the incidence of coronary heart disease in the general population," stated Koenig. "I believe we now have the ability to gain greater insight into the cardiovascular risk profile of individuals who have not already been diagnosed with the disease."

Incremental value of single resting ultrasensitive cardiac Troponin I measurement to rule-out myocardial ischemia
Yunus Tanglay, M.D., department of cardiology, Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland, presented the results of a study that determined that cTnI levels complement non-invasive clinical assessments in patients with suspected coronary artery disease (CAD). cTnI levels were measured using Singulex's highly sensitive cTnI research-use-only immunoassay in 714 patients without known CAD before and after a bicycle exercise stress-test. Myocardial ischemia (MIS) was detected in 167 (23.4%) patients, and cTnI levels were significantly higher in patients with MIS (4.0 ng/L [95% CI 2.8-8.6] vs. 2.6 ng/L [95% CI 1.8-4.1], p<0.001). Diagnostic accuracy of CAD increased when both clinical judgment and cTnI levels were considered prior to a patient's stress test.

Plasma Kidney Injury Molecule (KIM-1) and Endothelin-1 (ET-1) are associated with worsening renal function in Heart Failure patients
Eitan Friedman, M.D., division of cardiovascular medicine, Vanderbilt University Medical Center, Nashville, Tenn., stated that this study was the first to demonstrate that KIM-1 was not only quantifiable in plasma, but also serves as a biomarker for worsening renal function in heart failure (HF) patients. Elevation in urinary KIM-1 is a known indication of renal tubule epithelial damage, however, this study was the first to establish the biomarker's utility in plasma. ET-1, a low abundance, known plasma biomarker of endothelial function, was also found to be independently associated with worsening kidney function in HF patients. Renal dysfunction is a comorbidity of HF.

The following abstracts were presented in a poster presentation:

  • The clinical benefit of ultrasensitive cardiac Troponin I in the detection of exercise-induced myocardial ischemia
  • Novel dual-biomarker strategy and clinical judgment in the detection of exercise-induced myocardial ischemia
  • Subclinical inflammation quantified by Interleukin-6 for detection of exercise-induced myocardial ischemia
  • Cardiac Biomarkers pMMP-9, IL-6, and ET-1 are elevated in asymptomatic patients at risk of heart failure and associate with disease severity
  • Plasma Kidney Injury Molecule (KIM-1) and Endothelin-1 (ET-1) are associated with worsening renal function in Heart Failure patients
  • Glucagon like peptide-1 and blood pressure in young, healthy adults: a population-based study
  • Plasma glucagon-like-peptide 1 and body fat mass among young and healthy adults
  • Plasma endothelin-1 and risk of obstructive sleep apnea among young and healthy adults

Commenting on the significance of the abstract findings presented at the Congress, Guido Baechler, president and CEO of Singulex, stated, "Cardiovascular disease is the leading cause of death in the European Union, and thanks to our academic collaborators, we are even more confident that our SMC technology can offer a means to better detect, assess, and manage CVD patients, along- with associated comorbidities and risk factors. As these study findings indicate, with the launch of the SMC technology-based Sgx Clarity System in 2016, European physicians will have at their disposal a powerful diagnostic tool and unique portfolio of tests to drive evidence-based management of patients and improved outcomes."

For more information: visithttp://www.globenewswire.com/newsroom/ctr?d=10097361&l=14&a=www.singulex.com&u=http%3A%2F%2Fwww.singulex.comwww.singulex.com

Related Content

Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing| December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
Overlay Init